Vesting and Award of Options under LTIP

Abingdon Health

04/12/2025 07:00

RNS Number : 1748K

Abingdon Health PLC

04 December 2025

 

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

Vesting and Award of Options under LTIP

 

York, UK 4 December 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces updates, under the terms of the existing Long Term Incentive Plan established in December 2022 ("LTIP" or the "Plan"). The Plan issues share options ("Options") over ordinary shares of 0.025 pence each ("Ordinary Shares") to certain directors and senior management, in order to incentivise and encourage retention in a manner that aligns with the interests of the Company's shareholders.

 

Regarding the FY23 LTIP, 16% of the LTIPs awarded in December 2022 have now vested against performance criteria for the financial year ended 30 June 2025 ("FY25"), based on revenue and EBITDA targets. A total of 512,800 shares with an exercise price of 7 pence have vested as illustrated below, with 2,692,199 LTIP shares from the FY23 scheme lapsing.

 

PDMR
Role
Options vested and exercisable under the FY23 LTIP (FY23-FY25 inclusive)
Lapsed LTIP under the FY23 LTIP
Chris Hand
Executive Chairman
68,571
360,000
Chris Yates
Chief Commercial Officer President, Abingdon Health USA
205,714
1,080,000
Mark Jones
Chief Operating Officer
96,000
504,000
Nina Garrett
Chief Technical Officer
82,400
432,600
Candice Vendettuoli
Director of QARA
45,714
240,000
Natalie Thrush
Chief of Staff/Head of HR
14,400
75,600

 

In addition, under the terms of the Plan, the Company has awarded new nil cost LTIPs totalling 3,361,000 shares which will vest circa October 2028, following publication of audited accounts for the financial year ending 30 June 2028 ("FY28"), and subject to achieving performance targets based on revenue and EBITDA for performance in FY28.  50% of these new awards are based on achieving revenue targets and 50% are based on EBITDA targets.   

 

New and existing LTIPs are summarised below:

 

PDMR
Role
Existing LTIPs less those lapsed from FY23
New FY26 LTIPs
Total less lapsed FY23
Chris Hand
Executive Chairman
1,298,057
946,000
2,244,057
Tom Hayes
Chief Financial Officer
660,000
660,000
1,320,000
Chris Yates
Chief Commercial Officer President, Abingdon Health USA
2,002,173
555,000
2,557,173
Mark Jones
Chief Operating Officer
997,376
300,000
1,297,376
Nina Garrett
Chief Technical Officer
839,556
300,000
1,139,556
Candice Vendettuoli
Director of QARA
549,200
300,000
849,200
Natalie Thrush
Chief of Staff/Head of HR
383,207
300,000
683,207

 

 

The total LTIP share options outstanding, less those which have now lapsed from the FY23 scheme, from FY23, FY24, FY25 and FY26 is 10,090,570. If all these LTIP options were to vest and be exercised this equates to 3.86% of ordinary shares post exercise of options.

 

Enquiries:

 

Abingdon Health plc
www.abingdonhealth.com/investors/
Chris Hand, ExecutiveChairman
Via Walbrook PR
Tom Hayes, CFO
Zeus (Sole Broker and Nominated Adviser)
Tel: +44 (0)20 3829 5000
Antonio Bossi / Jacob Walker (Corporate Finance)
Walbrook PR (Media & Investor Relations)
Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus / Alice Woodings
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654


 

 

About Abingdon Health

 

Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.   

 

The Group's CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success. 

 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK.  Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.   The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities. 

 

Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.

 

Abingdon Health's brochure outlines the comprehensive support the Group can now provide to its international customers.  For more information visit: www.abingdonhealth.com.

 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name:
Chris Hand
2
Reason for the notification
a)
Position/Status:
Executive Chairman
b)
Initial Notification/Amendment:
Initial Notification
3
Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor
a)
Name:
Abingdon Health plc
b)
LEI:
213800XFI4WV3FBILO20
4.
Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.
a)
Description of the financial instrument:
Identification code:
Ordinary Shares of 0.025 pence each
GB00BLF79J41
b)
Nature of the transaction:
Award of LTIP Options
c)
Price(s) and volume(s):
Price(s)
Volume(s)
Nil
946,000
d)
Aggregated volume:
Price:
See above
e)
Date of the Transaction:
3 December 2025
f)
Place of the Transaction:
Outside a trading venue

 

 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name:
Chris Yates
2
Reason for the notification
a)
Position/Status:
Chief Commercial Officer / President, Abingdon Health USA
b)
Initial Notification/Amendment:
Initial Notification
3
Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor
a)
Name:
Abingdon Health plc
b)
LEI:
213800XFI4WV3FBILO20
4.
Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.
a)
Description of the financial instrument:
Identification code:
Ordinary Shares of 0.025 pence each
GB00BLF79J41
b)
Nature of the transaction:
Award of LTIP Options
c)
Price(s) and volume(s):
Price(s)
Volume(s)
Nil
555,000
d)
Aggregated volume:
Price:
See above
e)
Date of the Transaction:
3 December 2025
f)
Place of the Transaction:
Outside a trading venue

 

 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name:
Tom Hayes
2
Reason for the notification
a)
Position/Status:
Chief Financial Officer
b)
Initial Notification/Amendment:
Initial Notification
3
Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor
a)
Name:
Abingdon Health plc
b)
LEI:
213800XFI4WV3FBILO20
4.
Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.
a)
Description of the financial instrument:
Identification code:
Ordinary Shares of 0.025 pence each
GB00BLF79J41
b)
Nature of the transaction:
Award of LTIP Options
c)
Price(s) and volume(s):
Price(s)
Volume(s)
Nil
660,000
d)
Aggregated volume:
Price:
See above
e)
Date of the Transaction:
3 December 2025
f)
Place of the Transaction:
Outside a trading venue

 

 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name:
Mark Jones
2
Reason for the notification
a)
Position/Status:
Chief Operating Officer
b)
Initial Notification/Amendment:
Initial Notification
3
Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor
a)
Name:
Abingdon Health plc
b)
LEI:
213800XFI4WV3FBILO20
4.
Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.
a)
Description of the financial instrument:
Identification code:
Ordinary Shares of 0.025 pence each
GB00BLF79J41
b)
Nature of the transaction:
Award of LTIP Options
c)
Price(s) and volume(s):
Price(s)
Volume(s)
Nil
300,000
d)
Aggregated volume:
Price:
See above
e)
Date of the Transaction:
3 December 2025
f)
Place of the Transaction:
Outside a trading venue

 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name:
Nina Garrett
2
Reason for the notification
a)
Position/Status:
Chief Technical Officer
b)
Initial Notification/Amendment:
Initial Notification
3
Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor
a)
Name:
Abingdon Health plc
b)
LEI:
213800XFI4WV3FBILO20
4.
Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.
a)
Description of the financial instrument:
Identification code:
Ordinary Shares of 0.025 pence each
GB00BLF79J41
b)
Nature of the transaction:
Award of LTIP Options
c)
Price(s) and volume(s):
Price(s)
Volume(s)
Nil
300,000
d)
Aggregated volume:
Price:
See above
e)
Date of the Transaction:
3 December 2025
f)
Place of the Transaction:
Outside a trading venue

 

 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name:
Candice Vendettuoli
2
Reason for the notification
a)
Position/Status:
Director of QARA
b)
Initial Notification/Amendment:
Initial Notification
3
Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor
a)
Name:
Abingdon Health plc
b)
LEI:
213800XFI4WV3FBILO20
4.
Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.
a)
Description of the financial instrument:
Identification code:
Ordinary Shares of 0.025 pence each
GB00BLF79J41
b)
Nature of the transaction:
Award of LTIP Options
c)
Price(s) and volume(s):
Price(s)
Volume(s)
Nil
300,000
d)
Aggregated volume:
Price:
See above
e)
Date of the Transaction:
3 December 2025
f)
Place of the Transaction:
Outside a trading venue

 

 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name:
Natalie Thrush
2
Reason for the notification
a)
Position/Status:
Chief of Staff / Head of HR
b)
Initial Notification/Amendment:
Initial Notification
3
Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor
a)
Name:
Abingdon Health plc
b)
LEI:
213800XFI4WV3FBILO20
4.
Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.
a)
Description of the financial instrument:
Identification code:
Ordinary Shares of 0.025 pence each
GB00BLF79J41
b)
Nature of the transaction:
Award of LTIP Options
c)
Price(s) and volume(s):
Price(s)
Volume(s)
Nil
300,000
d)
Aggregated volume:
Price:
See above
e)
Date of the Transaction:
3 December 2025
f)
Place of the Transaction:
Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHUPGBWPUPAPPW